Articles On NeuroScientific Biopharmaceuticals (ASX:NSB)

Special Report: Early stage biotech NeuroScientific Biopharmaceuticals is developing peptide-based compounds that may prevent neurodegeneration and stimulate neuroregeneration. While its ... Read More The post NeuroScientific Biopharmaceuti...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is up 20% today on the back of an ASX announcement about its lead compound EmtinB. In a preclinical study, the compound demonstrated positive preliminary results in a Multip...

NeuroScientific Biopharmaceuticals (ASX: NSB) has published positive preliminary results from a pre-clinical study of its lead compound EmtinB in treating multiple sclerosis (MS). The full report is set to be published by the end of this mo...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Backpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a greater risk in the suburb’s sandy stews. Antibiotic maker Recce Pharmaceuticals (ASX: RCE) says its lead candidate is proving to be effective ag...

Our summary of NeuroScientific Biopharmaceuticals Ltd's recent announcement What's happened? NeuroScientific Biopharmaceuticals Ltd (ASX: NSB, “NeuroScientific”) has announced it has received the Final Report from its recently completed gl...

The COVID-19 pandemic will result in changes to several industries and one of these is manufacturing. Since the early 1960s manufacturing as a percentage of Australian GDP has dropped from 30 per cent to 5.7 per cent now. Of course Australi...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, only nine were in positive territory over the last fortnight; nine were flat and 119 saw their share prices fall. Cod...

NeuroScientific Biopharmaceuticals (ASX: NSB) has achieved positive results in pre-clinical studies using its lead drug candidate EmtinB to treat multiple sclerosis models. Independent research organisation Neuron Experts undertook the stud...

NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed positive results from a glaucoma study on pig models that indicates the “disease-modifying potential” of its lead drug candidate EmtinB. The drug developer today announced outcomes...

Dementia already affects hundreds of thousands of people in Australia, and it’s only going to get worse if a medical miracle is not forthcoming. The term relates to brain diseases, including Alzheimers, that impact a person’s ability to thi...

ImpediMed’s (ASX:IPD) December quarter report includes the word ‘up’ eight times and the word ‘down’ not at all, and yet the company’s shares dropped nearly 17 per cent at market open. The stock fell from 17c to 14c. ImpediMed expects to on...

You may have heard the saying “it’s not brain surgery” in the context of trying to prove something easy. Well there is a reason  — our brains are among the most difficult parts of our body to treat. There are a few ASX small caps trying to...

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

Cancer is a crowded market, pot has sleep and pain issues covered — or so they say — and companies dip in and out of respiratory diseases all the time. But there are a few ASX-listed stocks that are tackling health issues that still rate as...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Investors, brokers, high-ranking delegates, big pharma and Aussie small caps will all be sharing a room at the upcoming AusBiotech Invest & Partnering 2019 event in late October. The southern hemisphere’s biggest biotech investment even...

Special Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 guests attending the event last week. Hosted by industry entrepreneur Brian Leedman, the luncheon was established to raise awareness of, and bu...

The WA investment community will turn its attention to healthcare next Thursday, when the annual Biotech Lunch takes place in Perth. Hosted by industry entrepreneur Brian Leedman, the luncheon will provide a forum for brokers and investors...

Drug developer NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed the first pre-clinical results of an ophthalmology program that has demonstrated the potential for its lead drug candidate EmtinB to become a “revolutionary” treatmen...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on...

On Stockhead today: our report on the 100 best performing stocks for the year, how four directors put in $5.1 million to make a quick $1.4 million, what are the hottest stocks on the ASX right now and Dr Boreham’s prognosis of Suda. But fir...

At Stockhead we are as amazed as our readers when stocks rise by over 100 per cent in a day. But its a more common occurrence than we thought. There have been 23 stocks that have achieved that feat. The three most common reasons are success...

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price skyrocketed 190% on Tuesday after news that the company’s flagship drug EmtinB was part of a successful study into the treatment of Alzheimer’s disease as well as a range of...

The share price of Neuroscientific Biopharmaceuticals Ltd [ASX:NSB] is up a massive 175.86% trading at 40 cents following the end of its trading halt - the company announced today ‘breakthrough’ results for its Alzheimer’s drug and investor...

Alzheimer’s treatment could be set for a significant boost following the publication of what NeuroScientific Biopharmaceuticals (ASX: NSB) calls a “breakthrough study” into its lead drug candidate EmtinB using rat tissue. Contract researche...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...